Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $4.6 million.

  • vTv Therapeutics' Change in Accured Expenses rose 91185.84% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 20655.35%. This contributed to the annual value of -$5.2 million for FY2024, which is 27804.71% down from last year.
  • As of Q3 2025, vTv Therapeutics' Change in Accured Expenses stood at $4.6 million, which was up 91185.84% from $1.0 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Change in Accured Expenses high stood at $4.6 million for Q3 2025, and its period low was -$3.0 million during Q3 2022.
  • Over the past 5 years, vTv Therapeutics' median Change in Accured Expenses value was -$129000.0 (recorded in 2021), while the average stood at $182210.5.
  • In the last 5 years, vTv Therapeutics' Change in Accured Expenses tumbled by 214341.09% in 2022 and then skyrocketed by 91185.84% in 2025.
  • Over the past 5 years, vTv Therapeutics' Change in Accured Expenses (Quarter) stood at $3.3 million in 2021, then plummeted by 83.21% to $561000.0 in 2022, then increased by 17.47% to $659000.0 in 2023, then plummeted by 281.94% to -$1.2 million in 2024, then skyrocketed by 482.57% to $4.6 million in 2025.
  • Its Change in Accured Expenses was $4.6 million in Q3 2025, compared to $1.0 million in Q2 2025 and -$836000.0 in Q1 2025.